Trial · NCT06016634
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
NCT06016634, Phase 2, Recruiting, University of California, Davis
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Alendronate for Osteonecrosis in Adults With Sickle Cell Disease. Trials, record NCT06016634. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06016634
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
- NCT number
- NCT06016634
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 30 participants, estimated
- Lead sponsor
- University of California, Davis
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis, Avascular Necrosis
- Interventions
- Alendronate Sodium
- First posted
- 2023-08-30
- Last updated
- 2026-07-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment and retention rates | up to 28 weeks | Proportion of eligible patients who get recruited to the study; number of enrolled patients who complete 6-month study |
| Primary | Incidence of Treatment-Emergent Adverse Events as assessed by participant report | up to 28 weeks | Collect all adverse events reported by patients and determine if related to study drug |
| Primary | Pain assessed by the Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact questionnaire | up to 28 weeks | The Adult Sickle Cell Quality of Life Measurement System (ASCQ-Me) Pain Impact questionnaire is a patient-reported outcome measure of pain level in the past 7 days. The ASCQ-Me pain scale ranges from 0-100, with a standardized mean of 50 and a standard deviation of 10, where lower scores signify worse disease impact. |
| Secondary | Bone turnover markers | Baseline, then every 2 months until end of study | Measure longitudinal changes in of biomarkers for osteoclast (bone resorption) and osteoblast (bone formation) activity |
| Secondary | Inflammatory biomarkers | Baseline, then every 2 months until the end of the study | Measure longitudinal changes in inflammatory biomarkers from baseline to the end of the study |
| Secondary | Vascular adhesion biomarkers | Baseline, then every 2 months until the end of the study | Measure longitudinal changes in biomarkers of vascular adhesion from baseline until the end of the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL148310 | A feasibility study of alendronate therapy for osteonecrosis of the femoral head in adults with sickle cell disease | ADESINA, OYEBIMPE OLUYEMISI | UNIVERSITY OF CALIFORNIA AT DAVIS | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2021 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06016634
GET https://conductscience.org/api/trials/v1/NCT06016634/registered